跳至主要内容
临床试验/NCT05032261
NCT05032261已完成不适用

Norepinephrine Load and Relationship With Prognosis in Critically Patients With Circulatory Shock

Centre Hospitalier Universitaire de Nīmes1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2021年9月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
100
试验地点
1
主要终点
Mortality

研究概览

简要总结

Norepinephrine is recommended as first-line vasopressor in critically ill patients, regardless of shock etiology. Its advantages over dopamine and/or epinephrine have been demonstrated, especially by reducing tachycardia events. The current guidelines recommend a mean arterial pressure of at least 65 mmHg that in the resuscitation from sepsis-induced hypoperfusion. Some study reported that delay in initiation of vasopressor therapy was associated with an increase mortality risk in patient with septic shock .The recent experts' opinion suggest that " vasopressors should be started early, before (complete) completion of fluid ressuscitation ".

In the event of refractory septic shock, high-dose vasopressors may be used. The precise maximal dose of norepinephrine associated with mortality excess has been poorly studied. High doses have been defined by a cutoff value ranging from 0.5 μg/kg/min to 2 μg/kg/min and recently by 1 μg/kg/min for mortality at 90% and by 0,75 μg/kg/min for mortality at 60%. Furthermore, an increasing vasopressor dosing intensity during the first 24 hours after shock septic was associated with increased mortality depending of fluid administration. If a threshold value of norepinephrine score can be obtained, it could indicate the association with another vasopressor such as vasopressin or surrogates.

The primary aim of the present study aimed to confirm if a given norepinephrine dose is associated with mortality. The secondary aims were the link between mortality and norepinephrine duration, cumulative dose in order to build a score that predicts a futility of increasing norepinephrine dose.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age > 18 years
  • circulatory shock and admitted in ICU
  • with norepinephrine
  • Exclusion Criteria : Patient without norepinephrine or missing data.

排除标准

  • 未提供

研究组 & 干预措施

Group 1: surviving Patients

Patients surviving within 5 days of the date of ICU admission for circulatory shock and receiving norepinephrine

干预措施: Circulatory shock with norepinephrine in ICU (Drug)

Group 2: Deceased patients

Patients deceased within 5 days of the date of ICU admission for circulatory shock and receiving norepinephrine

干预措施: Circulatory shock with norepinephrine in ICU (Drug)

结局指标

主要结局

Mortality

时间窗: Day 5

Mortality within 5 days of the date of ICU admission for circulatory shock according to norepinephrine intensity

次要结局

  • Intensity(Day 5)
  • Time/Dose Ratio(Day 5)
  • Norepinephrine dose(Day 5)

研究者

发起方
Centre Hospitalier Universitaire de Nīmes
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

ICU Norepinephrine Load | 临床试验